Artificial Cell Death Polypeptide For Chimeric Antigen Receptor And Uses Thereof
AssigneeCentury Therapeutics, Inc.
InventorsMichael Naso, Jill Carton, John Wheeler, Luis Borges
Life of this patent
Estimating the term…
Abstract
Provided are polynucleotides encoding inactivated cell surface receptors. Also provided are genetically engineered induced pluripotent stem cells (iPSCs) and derivative cells thereof expressing a chimeric antigen receptor (CAR) and methods of using the same. Also provided are compositions, polypeptides, vectors, and methods of manufacturing.
Claims20
A polynucleotide encoding an inactivated cell surface receptor that comprises a monoclonal antibody-specific epitope and a cytokine, such as an interleukin 15 (IL-15) or an interleukin 2 (IL-2), wherein the monoclonal antibody-specific epitope and the cytokine are operably linked by an autoprotease peptide.
A polynucleotide consisting of operably linked polynucleotides encoding a truncated epithelial growth factor (tEGFR) variant having the amino acid sequence of SEQ ID NO:
- 71, an autoprotease peptide having the amino acid sequence of SEQ ID NO:
- 73, and an interleukin 15 (IL-15) having the amino acid sequence of SEQ ID NO:
- 72.
A polynucleotide encoding an inactivated cell surface receptor that comprises an epitope specifically recognized by an antibody selected from the group consisting of cetuximab, matuzumab, necitumumab, paniturnurnab, polatuzumab vedotin, rituximab and trastuzunab, and an IL-15, wherein the epitope and the cytokine are operably linked by a P2A sequence.
Dependencies are inferred from the claim text.